Press Release CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026 13 hours ago
Press Release CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results Aug 3